- Home
- CTNM vs CGC Comparison
CTNM vs CGC Comparison
Compare CTNM & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- CGC
- Stock Information
- Founded
- CTNM 2009
- CGC 2009
- Country
- CTNM United States
- CGC Canada
- Employees
- CTNM N/A
- CGC N/A
- Industry
- CTNM
- CGC Pharmaceuticals and Biotechnology
- Sector
- CTNM
- CGC Health Care
- Exchange
- CTNM Nasdaq
- CGC Nasdaq
- Market Cap
- CTNM 377.6M
- CGC 379.3M
- IPO Year
- CTNM 2024
- CGC N/A
- Fundamental
- Price
- CTNM $11.28
- CGC $2.23
- Analyst Decision
- CTNM Strong Buy
- CGC Sell
- Analyst Count
- CTNM 4
- CGC 1
- Target Price
- CTNM $29.25
- CGC $2.00
- AVG Volume (30 Days)
- CTNM 135.4K
- CGC 5.9M
- Earning Date
- CTNM 02-16-2025
- CGC 02-07-2025
- Dividend Yield
- CTNM N/A
- CGC N/A
- EPS Growth
- CTNM N/A
- CGC N/A
- EPS
- CTNM N/A
- CGC N/A
- Revenue
- CTNM N/A
- CGC $207,628,706.00
- Revenue This Year
- CTNM N/A
- CGC N/A
- Revenue Next Year
- CTNM N/A
- CGC $2.35
- P/E Ratio
- CTNM N/A
- CGC N/A
- Revenue Growth
- CTNM N/A
- CGC N/A
- 52 Week Low
- CTNM $11.38
- CGC $2.15
- 52 Week High
- CTNM $22.00
- CGC $14.92
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- CGC 26.31
- Support Level
- CTNM N/A
- CGC $2.15
- Resistance Level
- CTNM N/A
- CGC $2.29
- Average True Range (ATR)
- CTNM 0.00
- CGC 0.15
- MACD
- CTNM 0.00
- CGC -0.02
- Stochastic Oscillator
- CTNM 0.00
- CGC 8.70
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About CGC Canopy Growth Corporation
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.